Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. IGEA Pharma N.V.
  6. Summary
    IGPH   NL0012768675

IGEA PHARMA N.V.

(IGPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
0.31(c) 0.31(c) 0.31(c) 0.31(c) 0.31 Last
100 19 400 100 100 100 Volume
+3.33% 0.00% 0.00% 0.00% 0.00% Change
More quotes
Estimated financial data (e)
Sales 2021 0,14 M 0,16 M 0,16 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Sales 2022 51,1 M 57,6 M 57,6 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 99,9 M 113 M 113 M
Capi. / Sales 2021 714x
Capi. / Sales 2022 1,96x
Nbr of Employees 2
Free-Float 82,3%
More Financials
Company
IGEA Pharma NV is a biopharmaceutical company based in the Netherlands. The Company focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The Company develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or... 
More about the company
All news about IGEA PHARMA N.V.
11/25IGEA PHARMA N : GBC Research report IGEA Pharma N.V.
PU
11/25IGEA PHARMA N : GBC AG Publishes initial equity research report with buy recommendation an..
PU
11/25IGEA PHARMA N.V. : Gbc ag publishes initial equity research report with buy recommendation..
EQ
10/04IGEA PHARMA N : GBC AG to start equity coverage of IGEA Pharma
PU
10/01IGEA PHARMA N : H1 Loss Narrows on Gains From Financial Liabilities, Sale of Assets
MT
09/30IGEA Pharma N.V. Reports Earnings Results for First Half 2021
CI
09/30Igea Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
09/30IGEA PHARMA N : discloses its half-2021 financials
PU
09/27IGEA PHARMA N : has been granted the listing of the new shares from SIX Exchange Regulatio..
PU
09/08IGEA PHARMA N : to submit the listing prospectus to the SIX following the business combina..
PU
08/02IGEA PHARMA N : to boost revenues entering the growing cannabis market
PU
08/02IGEA PHARMA N : Expects Earnings, Revenue Boost On Blue Sky Natural Resources Deal
MT
07/26IGEA PHARMA N : Declares All-Equity Offer for Blue Sky Natural Resources Unconditional
MT
07/09IGEA PHARMA N : Minutes of the AGM 9 July 2021 + Attendance list
PU
07/09IGEA PHARMA N : announces Annual General Meeting resolutions
PU
More news
News in other languages on IGEA PHARMA N.V.
11/29IGEA PHARMA N.V. (VON GBC AG) : Kaufen
11/22IGEA PHARMA N.V. (VON GBC AG) : Buy
10/01IGEA Pharma a réduit sa perte au 1er semestre 2021
10/01IGEA dämmt Verlust im ersten Halbjahr 2021 ein
10/01Igea Pharma réduit sa perte au premier semestre grâce à des gains provenant de dettes f..
More news
Chart IGEA PHARMA N.V.
Duration : Period :
IGEA Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,30 €
Average target price 1,05 €
Spread / Average Target 252%
Managers and Directors
Vicenzo Moccia Chairman-Management Board
Sector and Competitors
1st jan.Capi. (M$)
IGEA PHARMA N.V.-42.59%113
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.67.89%23 009
BIOMÉRIEUX1.73%15 682
10X GENOMICS, INC.1.90%15 407
DIASORIN S.P.A.3.88%10 914
NATERA, INC.-10.47%8 188